Patents by Inventor Thomas E. Tarara

Thomas E. Tarara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9744178
    Abstract: Embodiments of the present invention provide a dry powder composition comprising porous carrier particles associated with one, two, three or more micronized drugs or APIs wherein an ordered mixture between the micronized drug or drugs and the carrier particle results, such that the micronized drug or drugs adhere strongly to the carrier particles forming a stable ordered mixture of respirable agglomerates. Embodiments of the present invention further comprise a spray-drying process to create the respirable agglomerates. Embodiments of the present invention further relate to the use of the dry powder formulation comprising respirable agglomerates for the treatment of a patient having a disease or condition which is treatable thereby.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: August 29, 2017
    Assignee: Novartis AG
    Inventors: Michael Hartman, Thomas E Tarara, Patrick Teung, Jeffry G Weers
  • Patent number: 9554993
    Abstract: A pulmonary delivery medicament comprises a plurality of particulates, the particulates comprising a structural matrix and a water insoluble and/or crystalline active agent. The particulates have a geometric diameter of 0.5 to 50 ?m. The water insoluble active agent can be a fungicide, antibiotic, budesonide. A method of making the medicament comprises forming a liquid feedstock, and forming a feedstock suspension by suspending in the liquid feedstock, the active agent and an excipient capable of forming a structural matrix, such as a phospholipid. The feedstock suspension is spray dried to produce the particulates.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: January 31, 2017
    Assignee: Novartis AG
    Inventors: Thomas E. Tarara, Jeffrey G. Weers, Alexey Kabalnov, Ernest G. Schutt, Luis A. Dellamary
  • Publication number: 20160354388
    Abstract: Embodiments of the present invention provide a dry powder composition comprising porous carrier particles associated with one, two, three or more micronized drugs or APIs wherein an ordered mixture between the micronized drug or drugs and the carrier particle results, such that the micronized drug or drugs adhere strongly to the carrier particles forming a stable ordered mixture of respirable agglomerates. Embodiments of the present invention further comprise a spray-drying process to create the respirable agglomerates. Embodiments of the present invention further relate to the use of the dry powder formulation comprising respirable agglomerates for the treatment of a patient having a disease or condition which is treatable thereby.
    Type: Application
    Filed: August 17, 2016
    Publication date: December 8, 2016
    Applicant: Novartis AG
    Inventors: Michael Hartman, Thomas E. Tarara, Patrick Teung, Jeffry G. Weers
  • Patent number: 9452139
    Abstract: Embodiments of the present invention provide a dry powder composition comprising porous carrier particles associated with one, two, three or more micronized drugs or APIs wherein an ordered mixture between the micronized drug or drugs and the carrier particle results, such that the micronized drug or drugs adhere strongly to the carrier particles forming a stable ordered mixture of respirable agglomerates. Embodiments of the present invention further comprise a spray-drying process to create the respirable agglomerates. Embodiments of the present invention further relate to the use of the dry powder formulation comprising respirable agglomerates for the treatment of a patient having a disease or condition which is treatable thereby.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: September 27, 2016
    Assignee: Novartis AG
    Inventors: Michael Hartman, Thomas E Tarara, Patrick Teung, Jeffry G Weers
  • Patent number: 9439862
    Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: September 13, 2016
    Assignee: Novartis AG
    Inventors: Jeffry G Weers, Thomas E Tarara, Luis A Dellamary, Ernest G Schutt
  • Patent number: 9421166
    Abstract: The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: August 23, 2016
    Assignee: Novartis AG
    Inventors: Thomas E Tarara, Jeffry G Weers, Maria Geraldine Venthoye
  • Publication number: 20150374623
    Abstract: Dry powder formulations for inhalation and their use in the treatment diseases and conditions. The formulation contains a uniform blend of a first spray-dried powder and a second spray-dried powder. The first spray-dried powder contains spray-dried particles of a therapeutically active ingredient dispersed in a pharmaceutically acceptable hydrophobic excipient. The second spray-dried powder contains spray-dried particles formed from a pharmaceutically acceptable hydrophobic excipient but are substantially free of any therapeutically active ingredient. The active ingredient in the first spray-dried powder is loaded sufficiently high to compensate for the second spray-dried powder being substantially free of any active ingredient. A process for preparing such formulations is also described.
    Type: Application
    Filed: March 11, 2014
    Publication date: December 31, 2015
    Inventors: Jeffry Weers, Daniel Huang, Thomas E. Tarara, Danforth Miller
  • Patent number: 9050267
    Abstract: Dry powder formulations for inhalation comprising spray-dried particles and their use in the treatment of an obstructive or inflammatory airways disease. Each particle has a core of a first active ingredient in substantially crystalline form that is coated with a layer of a second active ingredient in substantially amorphous form that is dispersed in a pharmaceutically acceptable hydrophobic excipient. A process for preparing such formulations is also described.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: Jeffry G. Weers, Nagaraja Rao, Daniel Huang, Danforth Miller, Thomas E. Tarara
  • Publication number: 20140377361
    Abstract: A microparticle for drug delivery comprises an active agent and an excipient, the excipient comprising a metal ion-lipid complex. The metal ion is chosen from the group consisting of lanthanide metals, actinide metals, group IIa and IIIb metals, transition metals or mixtures thereof. The lipid comprises a phospholipid. The complex results in a glass transition temperature increase of the microparticle.
    Type: Application
    Filed: September 5, 2014
    Publication date: December 25, 2014
    Applicant: NOVARTIS AG
    Inventors: Luis A. DELLAMARY, Jean RIESS, Ernest G. SCHUTT, Jeffry G. WEERS, Thomas E. TARARA
  • Patent number: 8877162
    Abstract: A microparticle for drug delivery comprises an active agent and an excipient, the excipient comprising a metal ion-lipid complex. The metal ion is chosen from the group consisting of lanthanide metals, actinide metals, group IIa and IIIb metals, transition metals or mixtures thereof. The lipid comprises a phospholipid. The complex results in a glass transition temperature increase of the microparticle.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: November 4, 2014
    Assignee: Novartis AG
    Inventors: Luis A. Dellamary, Jean Reiss, Ernest G. Schutt, Jeffry G. Weers, Thomas E. Tarara
  • Publication number: 20140302147
    Abstract: Embodiments of the present invention provide a dry powder composition comprising porous carrier particles associated with one, two, three or more micronized drugs or APIs wherein an ordered mixture between the micronized drug or drugs and the carrier particle results, such that the micronized drug or drugs adhere strongly to the carrier particles forming a stable ordered mixture of respirable agglomerates. Embodiments of the present invention further comprise a spray-drying process to create the respirable agglomerates. Embodiments of the present invention further relate to the use of the dry powder formulation comprising respirable agglomerates for the treatment of a patient having a disease or condition which is treatable thereby.
    Type: Application
    Filed: March 10, 2014
    Publication date: October 9, 2014
    Applicant: NOVARTIS AG
    Inventors: Michael HARTMAN, Thomas E TARARA, Patrick TEUNG, Jeffry G WEERS
  • Publication number: 20140212504
    Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
    Type: Application
    Filed: April 2, 2014
    Publication date: July 31, 2014
    Inventors: Jeffry G. WEERS, Thomas E. TARARA, Luis A. DELLAMARY, Jean G. RIESS, Ernest G. SCHUTT
  • Publication number: 20140206638
    Abstract: The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.
    Type: Application
    Filed: April 8, 2014
    Publication date: July 24, 2014
    Applicant: NOVARTIS AG
    Inventors: Thomas E. TARARA, Jeffry G. WEERS, Geraldine VENTHOYE
  • Patent number: 8715623
    Abstract: A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 6, 2014
    Assignee: Novartis AG
    Inventors: Thomas E. Tarara, Jeffry G. Weers, Geraldine Venthoye
  • Patent number: 8709484
    Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders may include a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: April 29, 2014
    Assignee: Novartis AG
    Inventors: Jeffry G. Weers, Thomas E. Tarara, Luis A. Dellamary, Jean G. Riess, Ernest G. Schutt
  • Patent number: 8664187
    Abstract: The present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period of 20 to 36 days.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: March 4, 2014
    Assignee: Novartis AG
    Inventors: Peter Challoner, Carlos Rodriguez, Emil Samara, Thomas E Tarara, John D Lord
  • Publication number: 20130319411
    Abstract: Dry powder formulations for inhalation comprising spray-dried particles and their use in the treatment of an obstructive or inflammatory airways disease. Each particle has a core of a first active ingredient in substantially crystalline form that is coated with a layer of a second active ingredient in substantially amorphous form that is dispersed in a pharmaceutically acceptable hydrophobic excipient. A process for preparing such formulations is also described.
    Type: Application
    Filed: February 3, 2012
    Publication date: December 5, 2013
    Inventors: Jeffry G. Weers, Nagaraja Rao, Daniel Huang, Danforth Miller, Thomas E. Tarara
  • Publication number: 20130095153
    Abstract: A microparticle for drug delivery comprises an active agent and an excipient, the excipient comprising a metal ion-lipid complex. The metal ion is chosen from the group consisting of lanthanide metals, actinide metals, group IIa and IIIb metals, transition metals or mixtures thereof. The lipid comprises a phospholipid. The complex results in a glass transition temperature increase of the microparticle.
    Type: Application
    Filed: December 6, 2012
    Publication date: April 18, 2013
    Applicant: NOVARTIS AG
    Inventors: Luis A. DELLAMARY, Jean REISS, Ernest G. SCHUTT, Jeffry G. WEERS, Thomas E. TARARA
  • Patent number: 8404217
    Abstract: Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: March 26, 2013
    Assignee: Novartis AG
    Inventors: Thomas E. Tarara, Jeffry G. Weers, Michael A. Eldon, Rangachari Narashimhan, Andrew Clark
  • Patent number: 8349294
    Abstract: Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compositions of the present invention have superior stability to other microparticle compositions resulting in a microparticle composition with longer shelf life and improved dispersability. The microparticle compositions of the present invention have a transition temperature (Tg) of at least 20° C. above the recommended storage temperature (Tst) for drug delivery.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: January 8, 2013
    Assignee: Novartis AG
    Inventors: Luis A Dellamary, Jean Riess, Ernest G Schutt, Jeffry G Weers, Thomas E Tarara